{"id":"insulin-novorapid-versus-actrapid","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are insulin formulations used to manage blood glucose in diabetes. NovoRapid (insulin aspart) is a rapid-acting analog with onset within 10-20 minutes, peak effect at 1-3 hours, and duration of 3-5 hours, making it suitable for mealtime coverage. Actrapid (regular human insulin) has a slower onset of 30 minutes to 1 hour, peak at 2-4 hours, and longer duration of 6-8 hours, traditionally used for basal coverage or when rapid action is not required.","oneSentence":"NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, while Actrapid is a regular human insulin with a slower onset of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:17.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04149262","phase":"","title":"Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-15","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT06767761","phase":"PHASE3","title":"A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-18","conditions":"Diabetes","enrollment":580},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT04381429","phase":"PHASE4","title":"Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-08-17","conditions":"Cystic Fibrosis-related Diabetes","enrollment":38},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT04012138","phase":"PHASE4","title":"Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2019-12-20","conditions":"Hyperkalemia","enrollment":525},{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT00504673","phase":"PHASE3","title":"Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":277},{"nctId":"NCT00101751","phase":"PHASE4","title":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4877},{"nctId":"NCT00267683","phase":"PHASE3","title":"Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2005-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT00788840","phase":"PHASE4","title":"Detemir Energy Expenditure Study","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":30},{"nctId":"NCT03770767","phase":"PHASE3","title":"Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Pregnancy Complications","enrollment":216},{"nctId":"NCT02621489","phase":"PHASE4","title":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-12","conditions":"Atherosclerosis, Diabetes, Restenosis","enrollment":38},{"nctId":"NCT05767255","phase":"PHASE3","title":"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-12-01","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":66},{"nctId":"NCT03377699","phase":"PHASE3","title":"Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-22","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":225},{"nctId":"NCT03689374","phase":"PHASE3","title":"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":2274},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT03260868","phase":"PHASE4","title":"Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-19","conditions":"Type 1 Diabetes Mellitus","enrollment":15},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT00591227","phase":"PHASE4","title":"Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus","enrollment":176},{"nctId":"NCT04834362","phase":"PHASE4","title":"Insulin for Hyperglycemia in Stroke Trial","status":"COMPLETED","sponsor":"National Institute of Neurosciences and Hospital, Dhaka","startDate":"2021-04-05","conditions":"Hyperglycemia, Stroke, Acute","enrollment":452},{"nctId":"NCT03981627","phase":"PHASE1, PHASE2","title":"A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2019-06-06","conditions":"Type 1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT03511521","phase":"PHASE4","title":"Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2018-03-27","conditions":"Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes","enrollment":3},{"nctId":"NCT04055480","phase":"NA","title":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2019-08-10","conditions":"Type 1 Diabetes","enrollment":25},{"nctId":"NCT04222348","phase":"PHASE3","title":"MeDiGes Study: Metformine Use in Gestational Diabetes","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2016-10-26","conditions":"Diabetes, Gestational, Perinatal Disorder, Puerperal Disorder","enrollment":200},{"nctId":"NCT04184466","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-10-18","conditions":"Clamp Study","enrollment":26},{"nctId":"NCT04184492","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-04-15","conditions":"Clamp Study","enrollment":34},{"nctId":"NCT02590016","phase":"PHASE4","title":"Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Tampere University Hospital","startDate":"2015-09","conditions":"Gestational Diabetes, Hypoglycemia, Neonatal","enrollment":50},{"nctId":"NCT01850615","phase":"PHASE3","title":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":323},{"nctId":"NCT01835431","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-10-17","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":362},{"nctId":"NCT02582242","phase":"PHASE4","title":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-19","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":437},{"nctId":"NCT01109316","phase":"PHASE3","title":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-04","conditions":"Diabetes Mellitus, Type 1","enrollment":132},{"nctId":"NCT01526733","phase":"PHASE4","title":"Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2011-12","conditions":"Type 1 Diabetes Mellitus","enrollment":25},{"nctId":"NCT00906529","phase":"PHASE4","title":"Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-05","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT01774565","phase":"NA","title":"Closed-loop Insulin Delivery in the General Ward","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2016-08","conditions":"Diabetes Mellitus","enrollment":43},{"nctId":"NCT00523042","phase":"PHASE3","title":"Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-08-30","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT00322257","phase":"PHASE3","title":"Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-05-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":596},{"nctId":"NCT01755416","phase":"PHASE2","title":"Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-01","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT02509429","phase":"PHASE2","title":"Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-06-16","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT00417989","phase":"NA","title":"Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2007-01","conditions":"Type 1 Diabetes","enrollment":485},{"nctId":"NCT02420262","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-07-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02276859","phase":"PHASE4","title":"Normal Versus Dual Wave Insulin Bolus for High-protein Food","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2014-10","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT03244241","phase":"PHASE4","title":"Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study","status":"UNKNOWN","sponsor":"Merete Bechmann Christensen","startDate":"2017-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT01589653","phase":"PHASE4","title":"Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":155},{"nctId":"NCT00428207","phase":"NA","title":"Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy","status":"TERMINATED","sponsor":"Joslin Diabetes Center","startDate":"2007-02","conditions":"Type 1 Diabetes Mellitus","enrollment":4},{"nctId":"NCT00773279","phase":"PHASE3","title":"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-09","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":242},{"nctId":"NCT00614055","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":178},{"nctId":"NCT00613951","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":182},{"nctId":"NCT00509925","phase":"PHASE4","title":"Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-07","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":23},{"nctId":"NCT00474045","phase":"PHASE3","title":"Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":470},{"nctId":"NCT00184600","phase":"PHASE3","title":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT01388361","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT00612040","phase":"PHASE2","title":"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":178},{"nctId":"NCT00841087","phase":"PHASE2","title":"Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":65},{"nctId":"NCT00331604","phase":"PHASE3","title":"Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":618},{"nctId":"NCT00472953","phase":"PHASE3","title":"Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-05-15","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":38},{"nctId":"NCT00184626","phase":"PHASE4","title":"Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":97},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT01618214","phase":"PHASE4","title":"Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01123980","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT00469092","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01467141","phase":"PHASE4","title":"Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":26},{"nctId":"NCT01165684","phase":"PHASE4","title":"Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":401},{"nctId":"NCT00842361","phase":"PHASE2","title":"Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT00097084","phase":"PHASE3","title":"Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":324},{"nctId":"NCT00095082","phase":"PHASE3","title":"Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":447},{"nctId":"NCT02100475","phase":"PHASE3","title":"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":31},{"nctId":"NCT00097877","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT00097071","phase":"PHASE3","title":"Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":299},{"nctId":"NCT00071448","phase":"PHASE3","title":"Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":378},{"nctId":"NCT00365170","phase":"PHASE4","title":"Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":419},{"nctId":"NCT01045707","phase":"PHASE3","title":"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":530},{"nctId":"NCT01464099","phase":"PHASE1","title":"Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT01530048","phase":"PHASE1","title":"Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-03","conditions":"Diabetes, Healthy","enrollment":34},{"nctId":"NCT02887625","phase":"NA","title":"Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM","status":"UNKNOWN","sponsor":"Dr. Muhammad Abdulghani","startDate":"2015-02","conditions":"Type 2 Diabetes","enrollment":410},{"nctId":"NCT00795600","phase":"PHASE4","title":"Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT01039532","phase":"","title":"Comparison of Thrice Daily Biphasic Human Insulin With Basal Bolus Regimen in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT01865305","phase":"PHASE1","title":"Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT01892020","phase":"PHASE4","title":"Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":161},{"nctId":"NCT01240785","phase":"PHASE4","title":"Metformin Versus Insulin in Gestational Diabetes","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2006-06","conditions":"Gestational Diabetes","enrollment":221},{"nctId":"NCT01196104","phase":"PHASE3","title":"Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler","status":"TERMINATED","sponsor":"Mannkind Corporation","startDate":"2010-09","conditions":"Type 2 Diabetes","enrollment":39},{"nctId":"NCT01445951","phase":"PHASE3","title":"Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2011-09","conditions":"Type 1 Diabetes Mellitus","enrollment":518},{"nctId":"NCT00309244","phase":"PHASE3","title":"Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2006-02","conditions":"Diabetes Type 2","enrollment":677},{"nctId":"NCT00590226","phase":"PHASE4","title":"Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-12","conditions":"Type 2 Diabetes","enrollment":130},{"nctId":"NCT01474538","phase":"PHASE3","title":"Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":122},{"nctId":"NCT00657943","phase":"PHASE4","title":"The Copenhagen Insulin and Metformin Therapy Trial","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2008-04","conditions":"Type 2 Diabetes, Atherosclerosis, Arteriosclerosis","enrollment":415},{"nctId":"NCT00942318","phase":"PHASE4","title":"Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":52},{"nctId":"NCT00663624","phase":"PHASE4","title":"Management of Hyperglycemia in the ER: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care","status":"WITHDRAWN","sponsor":"Emory University","startDate":"","conditions":"Diabetes","enrollment":""},{"nctId":"NCT01889095","phase":"PHASE4","title":"Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-07","conditions":"Diabetes Type 2","enrollment":160},{"nctId":"NCT01079364","phase":"PHASE4","title":"Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":52},{"nctId":"NCT01134107","phase":"PHASE3","title":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 1","enrollment":133},{"nctId":"NCT01121835","phase":"PHASE4","title":"Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":934},{"nctId":"NCT00797823","phase":"PHASE2","title":"Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone","status":"COMPLETED","sponsor":"Legacy Health System","startDate":"2008-11","conditions":"Type 1 Diabetes","enrollment":14},{"nctId":"NCT00539396","phase":"PHASE2","title":"A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 1","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Insulin NovoRapid versus Actrapid","genericName":"Insulin NovoRapid versus Actrapid","companyName":"Odense University Hospital","companyId":"odense-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, while Actrapid is a regular human insulin with a slower onset of action. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}